FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL							
OMB Number:	3235-0104						
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

			2. Date of Event Requiring Statement (Month/Day/Year) 10/06/2022		3. Issuer Name and Ticker or Trading Symbol Tarsus Pharmaceuticals, Inc. [TARS]					
(Last)	(First)	(Middle)			onship of Reporting Person(s) to Is) Issuer		5. If Amendment, Date of Original Filed (Month/Day/Year)		
15440 LAGUNA CANYON ROAD, SUITE 160			X	Director	10% Owner					
(Street)			_	"	Officer (give title below)	Other (specify	below)		up Filing (Check Applicable Line) One Reporting Person	
IRVINE	CA	92673						Form filed by N	More than One Reporting Person	
(City)	(State)	(Zip)								
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)		2. Amount Owned (In	of Securities Beneficially str. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		Nature of Indirect Beneficial Ownership (Instr. 5)				
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
						ed				
1. Title of Derivati	ve Security (Instr. 4)			varrants, o		ed urities)	4. Conversi or Exerci		6. Nature of Indirect Beneficial Ownership (Instr. 5)	

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

/s/ Leonard M. Greenstein, Attorney-in-Fact 10/11/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Tarsus Pharmaceuticals, Inc. - Power of Attorney

KNOW ALL BY THESE PRESENTS, the undersigned hereby constitutes and appoints each of Bobak Azamian, Leo Greenstein, Bryan Wahl, Kim Norman, and

- (1) execute for and on behalf of the undersigned a Form ID Application, if required, and submit the same to the United States Securities and E:

(2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Tarsus Pharmaceuticals, Inc. (the "Company") or as a holder of 10% or more of the Company's securities, Forms

- (3) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such Fi
- (4) take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benue

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever

The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assured.

This Power of Attorney may be filed with the SEC as a confirming statement of the authority granted herein. This Power of Attorney shall remain undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below.

Date: October 6, 2022 By: /s/ Scott Morrison Name: Scott Morrison